Get started
GT BIOPHARMA INCGT BIOPHARMA INCGT BIOPHARMA INC

GT BIOPHARMA INC

No trades
See on Supercharts
Overview
Financials News Ideas Technicals

GTBP chart

Key stats

Market capitalization
‪4.71 M‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.15EUR
Net income (FY)
‪−7.03 M‬EUR
Revenue (FY)
—
Shares float
‪1.24 M‬
Beta (1Y)
1.58

About GT BIOPHARMA INC

Sector
Health Technology
CEO
Michael Breen
Headquarters
Brisbane
Website
gtbiopharma.com
Employees (FY)
2
Founded
1965
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GTBP is 0.55 EUR — it has decreased by 99.21% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange GT BIOPHARMA INC stocks are traded under the ticker GTBP.
GT BIOPHARMA INC is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
GTBP stock is ‪12.51 K‬% volatile and has beta coefficient of 1.58. Check out the list of the most volatile stocks — is GT BIOPHARMA INC there?
GTBP earnings for the last quarter are −1.71 EUR per share, whereas the estimation was −2.32 EUR resulting in a 26.29% surprise. The estimated earnings for the next quarter are −2.50 EUR per share. See more details about GT BIOPHARMA INC earnings.
Yes, you can track GT BIOPHARMA INC financials in yearly and quarterly reports right on TradingView.
GTBP net income for the last quarter is ‪−2.75 M‬ EUR, while the quarter before that showed ‪−2.22 M‬ EUR of net income which accounts for −24.01% change. Track more GT BIOPHARMA INC financial stats to get the full picture.
Today GT BIOPHARMA INC has the market capitalization of ‪12.91 M‬, it has increased by 114.06% over the last week.
No, GTBP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GTBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GT BIOPHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
GTBP reached its all-time high on Sep 11, 2017 with the price of 1973.85 EUR, and its all-time low was 0.55 EUR and was reached on Dec 24, 2020.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 2.00 employees. See our rating of the largest employees — is GT BIOPHARMA INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GT BIOPHARMA INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GT BIOPHARMA INC stock shows the strong sell signal. See more of GT BIOPHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.